Benzodiazepines in Alzheimer's disease: beneficial or detrimental effects
Dementia is considered a clinical syndrome characterized by cognitive dysfunction and
memory loss. Alzheimer's disease (AD) is the most common type of dementia. AD is linked …
memory loss. Alzheimer's disease (AD) is the most common type of dementia. AD is linked …
Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects
AN Edinoff, CA Nix, AS Odisho, CP Babin… - Neurology …, 2022 - mdpi.com
As tranquilizers, benzodiazepines have a wide range of clinical uses. Recently, there has
been a significant rise in the number of novel psychoactive substances, including designer …
been a significant rise in the number of novel psychoactive substances, including designer …
Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?
Efficient treatment of stress-related disorders, such as depression, is still a major challenge.
The onset of antidepressant drug action is generally quite slow, while the anxiolytic action of …
The onset of antidepressant drug action is generally quite slow, while the anxiolytic action of …
[HTML][HTML] Lower urinary tract symptoms in depression: a review
DJ Anderson, A Aucoin, CR Toups… - Health psychology …, 2023 - ncbi.nlm.nih.gov
Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …
population as patients age with approximately a third of individuals experiencing LUTS …
Insights on benzodiazepines' potential in Alzheimer's disease
Alzheimer's disease (AD) is the most frequent type of dementia characterized by the
deposition of amyloid beta (Aβ) plaque and tau-neurofibrillary tangles (TNTs) in the brain …
deposition of amyloid beta (Aβ) plaque and tau-neurofibrillary tangles (TNTs) in the brain …
[HTML][HTML] Mental health and drug use in college students: Should we take action?
Background College students are vulnerable to suffering from anxiety and depression.
Moreover, mental disorders can contribute to drug consumption or inappropriate use of …
Moreover, mental disorders can contribute to drug consumption or inappropriate use of …
Local and global effects of sedation in resting-state fMRI: a randomized, placebo-controlled comparison between etifoxine and alprazolam
TSPO ligands are promising alternatives to benzodiazepines in the treatment of anxiety, as
they display less pronounced side effects such as sedation, cognitive impairment, tolerance …
they display less pronounced side effects such as sedation, cognitive impairment, tolerance …
Hybridization of the effective pharmacophores for treatment of epilepsy: design, synthesis, in vivo anticonvulsant activity, and in silico studies of phenoxyphenyl-1, 3, 4 …
A Fakhrioliaei, F Abedinifar, P Salehi Darjani… - BMC chemistry, 2023 - Springer
Background Epilepsy is a common neurological disorder. The available drugs for this
disease only control convulsions in nearly 70% of patients, while bearing many side effects …
disease only control convulsions in nearly 70% of patients, while bearing many side effects …
The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials
F Rossano, C Caiazza, N Zotti, L Viacava… - European …, 2023 - Elsevier
Azapirones have been proposed as anxiety and mood modulators. We assessed
azapirones' viability in anxiety disorders via systematic review and random-effects meta …
azapirones' viability in anxiety disorders via systematic review and random-effects meta …
[HTML][HTML] Have effective antidepressants finally arrived? Developments in major depressive disorder therapy
ME Thase - The Journal of Clinical Psychiatry, 2023 - psychiatrist.com
Among the greatest unmet needs in major depressive disorder (MDD) is a lack of effective
pharmacotherapies for patients who do not respond to first-and second-line antidepressant …
pharmacotherapies for patients who do not respond to first-and second-line antidepressant …